CELU - Celularity Inc. Stock Price, Fair Value and News

3.14USD+0.15 (+5.02%)Market Closed

Market Summary

USD3.14+0.15

Market Closed

5.02%

CELU Stock Price

View Fullscreen

CELU RSI Chart

CELU Valuation

Market Cap

618.2M

Price/Earnings (Trailing)

-3.77

Price/Sales (Trailing)

46.26

EV/EBITDA

-0.56

Price/Free Cashflow

-10.5

CELU Price/Sales (Trailing)

CELU Profitability

EBT Margin

-1226.64%

Return on Equity

-599.76%

Return on Assets

-115.41%

Free Cashflow Yield

-9.53%

CELU Fundamentals

CELU Revenue

Revenue (TTM)

14.8M

CELU Earnings

Earnings (TTM)

-181.4M

Breaking Down CELU Revenue

Last 7 days

4.0%

Last 30 days

5.7%

Last 90 days

4.0%

Trailing 12 Months

718.8%

How does CELU drawdown profile look like?

CELU Financial Health

Current Ratio

0.19

Debt/Equity

0.56

Debt/Cashflow

-3.75

CELU Investor Care

Shares Dilution (1Y)

30.12%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	16.0M	15.1M	14.8M	0
2022	24.6M	25.2M	18.7M	18.0M
2021	13.5M	12.5M	19.7M	21.3M
2020	18.9M	0	16.6M	14.3M
2019	0	0	0	21.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Celularity Inc.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

CEO	Dr. Robert Joseph Hariri M.D., Ph.D.
WEBSITE	celularity.com
INDUSTRY	Biotechnology
EMPLOYEES	225

Celularity Inc. Frequently Asked Questions

What is the ticker symbol for Celularity Inc.? What does CELU stand for in stocks?

CELU is the stock ticker symbol of Celularity Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Celularity Inc. (CELU)?

As of Fri Jul 26 2024, market cap of Celularity Inc. is 618.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CELU stock?

You can check CELU's fair value in chart for subscribers.

Is Celularity Inc. a good stock to buy?

The fair value guage provides a quick view whether CELU is over valued or under valued. Whether Celularity Inc. is cheap or expensive depends on the assumptions which impact Celularity Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CELU.

What is Celularity Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, CELU's PE ratio (Price to Earnings) is -3.77 and Price to Sales (PS) ratio is 46.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CELU PE ratio will change depending on the future growth rate expectations of investors.